Europe minimal residual disease (MRD) testing market was valued at $ 265.6 million in 2021 and will grow by 11.8% annually over 2021-2031, driven by the rising prevalence of hematological malignancy and cancer, the aging population, technological advancements in diagnostics and therapies due to increasing R&D investment, and the growing healthcare expenditure.
Highlighted with 37 tables and 55 figures, this 115-page report 鈥淓urope Minimal Residual Disease (MRD) Testing 麻豆原创 2021-2031 by Offering (Services, Test Kits & Consumables), Application (NHL, MM, ALL, CLL, AML, CML, HL, Solid Tumor), Technology (Flow Cytometry, PCR, NGS, Others), End User (Hospitals and Clinics, Research Institutions, Diagnostic Laboratories, Others), and Country: Trend Forecast and Growth Opportunity鈥� is based on a comprehensive research of the entire Europe minimal residual disease (MRD) testing market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2018-2021 and provides forecast from 2022 till 2031 with 2021 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
In-depth qualitative analyses include identification and investigation of the following aspects:
鈥� 麻豆原创 Structure
鈥� Growth Drivers
鈥� Restraints and Challenges
鈥� Emerging Product Trends & 麻豆原创 Opportunities
鈥� Porter鈥檚 Fiver Forces
The trend and outlook of Europe market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19 and Russia-Ukraine conflict. The balanced (most likely) projection is used to quantify Europe minimal residual disease (MRD) testing market in every aspect of the classification from perspectives of Offering, Application, Technology, End User, and Country.
Based on Offering, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Services
鈥� Test Kits & Consumables
Based on Application, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Non-Hodgkin's Lymphoma (NHL)
o DLBCL
o Marginal Zone Lymphoma
o Follicular Lymphoma
o Peripheral T-cell Lymphoma
o Mantle Cell Lymphoma
o Other NHLs
鈥� Multiple Myeloma (MM)
鈥� Acute Lymphoblastic Leukemia (ALL)
鈥� Chronic Lymphoblastic Leukemia (CLL)
鈥� Acute Myeloid Leukemia (AML)
鈥� Chronic Myeloid Leukemia (CML)
鈥� Hodgkin's Lymphoma (HL)
鈥� Solid Tumor
鈥� Other Applications
By Technology, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Flow Cytometry
鈥� Polymerase Chain Reaction (PCR)
鈥� Next-Generation Sequencing (NGS)
鈥� Other Technologies
By End User, the Europe market is segmented into the following sub-markets with annual revenue ($ mn) for 2021-2031 included in each section.
鈥� Hospitals and Clinics
鈥� Research Institutions
鈥� Diagnostic Laboratories
鈥� Other End Users
Geographically, the following national/local markets are fully investigated:
鈥� Germany
鈥� UK
鈥� France
鈥� Spain
鈥� Italy
鈥� Netherlands
鈥� Rest of Europe (further segmented into Russia, Switzerland, Poland, Sweden, Belgium, Austria, Ireland, Norway, Denmark, and Finland)
For each key country, detailed analysis and data for annual revenue ($ mn) are available for 2021-2031. The breakdown of national markets by Application, Technology, and End User over the forecast years are also included.
The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
1 Introduction 7
1.1 Industry Definition and Research Scope 7
1.1.1 Industry Definition 7
1.1.2 Research Scope 8
1.2 Research Methodology 11
1.2.1 Overview of 麻豆原创 Research Methodology 11
1.2.2 麻豆原创 Assumption 12
1.2.3 Secondary Data 12
1.2.4 Primary Data 12
1.2.5 Data Filtration and Model Design 13
1.2.6 麻豆原创 Size/Share Estimation 14
1.2.7 Research Limitations 15
1.3 Executive Summary 16
2 麻豆原创 Overview and Dynamics 19
2.1 麻豆原创 Size and Forecast 19
2.1.1 Impact of COVID-19 on World Economy 20
2.1.2 Impact of COVID-19 on the 麻豆原创 22
2.2 Major Growth Drivers 24
2.3 麻豆原创 Restraints and Challenges 30
2.4 Emerging Opportunities and 麻豆原创 Trends 33
2.5 Porter鈥檚 Fiver Forces Analysis 37
3 Segmentation of Europe 麻豆原创 by Offering 41
3.1 麻豆原创 Overview by Offering 41
3.2 Services 43
3.3 Test Kits & Consumables 44
4 Segmentation of Europe 麻豆原创 by Application 45
4.1 麻豆原创 Overview by Application 45
4.2 Non-Hodgkin鈥檚 Lymphoma (NHL) 47
4.2.1 DLBCL 49
4.2.2 Marginal Zone Lymphoma 50
4.2.3 Follicular Lymphoma 51
4.2.4 Peripheral T-cell Lymphoma 52
4.2.5 Mantle Cell Lymphoma 53
4.2.6 Other NHLs 54
4.3 Multiple Myeloma (MM) 55
4.4 Acute Lymphoblastic Leukemia (ALL) 56
4.5 Chronic Lymphoblastic Leukemia (CLL) 57
4.6 Acute Myeloid Leukemia (AML) 58
4.7 Chronic Myeloid Leukemia (CML) 59
4.8 Hodgkin鈥檚 Lymphoma (HL) 60
4.9 Solid Tumor 61
4.10 Other Applications 62
5 Segmentation of Europe 麻豆原创 by Technology 63
5.1 麻豆原创 Overview by Technology 63
5.2 Flow Cytometry 65
5.3 Polymerase Chain Reaction (PCR) 66
5.4 Next-Generation Sequencing (NGS) 67
5.5 Other Technologies 68
6 Segmentation of Europe 麻豆原创 by End User 69
6.1 麻豆原创 Overview by End User 69
6.2 Hospitals and Clinics 71
6.3 Research Institutions 72
6.4 Diagnostic Laboratories 73
6.5 Other End Users 74
7 European 麻豆原创 2021-2031 by Country 75
7.1 Overview of European 麻豆原创 75
7.2 Germany 78
7.3 U.K. 80
7.4 France 82
7.5 Spain 84
7.6 Italy 86
7.7 Netherlands 88
7.8 Rest of European 麻豆原创 90
8 Competitive Landscape 92
8.1 Overview of Key Vendors 92
8.2 New Product Launch, Partnership, Investment, and M&A 96
8.3 Company Profiles 97
Adaptive Biotechnologies Corporation 97
ArcherDX, Inc. (Invitae Corporation) 99
Arup Laboratories 100
Asuragen Inc. 101
Bio-Rad Laboratories, Inc. 102
Cergentis B.V. 103
Guardant Health 104
ICON plc 105
Inivata Ltd. 106
Invivoscribe, Inc. 107
Laboratory Corporation of America Holdings 108
Mission Bio, Inc. 109
Natera, Inc. 110
NeoGenomics Laboratories, Inc. 111
Opko Health, Inc. 112
Quest Diagnostics Incorporated 113
Sysmex Corporation 114
RELATED REPORTS 115
Selected Key Players:
Adaptive Biotechnologies Corporation
ArcherDX, Inc. (Invitae Corporation)
Arup Laboratories
Asuragen Inc.
Bio-Rad Laboratories, Inc.
Cergentis B.V.
Guardant Health
ICON plc
Inivata Ltd.
Invivoscribe, Inc.
Laboratory Corporation of America Holdings
Mission Bio, Inc.
Natera, Inc.
NeoGenomics Laboratories, Inc.
Opko Health, Inc.
Quest Diagnostics Incorporated
Sysmex Corporation
(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
听
听
*If Applicable.
